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Formation of stable blood clots requires formation of glutamyl-6-lysyl peptide cross- 
links between certain glutamyl and lysyl residues in fibrin. Formation of these cross- 
links is catalyzed by the transamidase factor XIIL. Production of this enzyme is 
initiated by thrombin-catalyzed limited proteolysis of the inactive zymogen factor XI11 
during the final stage of the blood clotting cascade.' This initial proteolytic event in 
the reaction pathway for conversion of factor XI11 to factor XIIL involves cleavage 
at Arg-a36 and release of a 36 amino acid residue activation peptide from the a chains 
of the qbz  molecules comprising plasma factor XIII? 
Using an HPLC procedure developed to monitor the release of peptides upon 
treatment of human factor XI11 with human a-thrombin, two peptides, AP and AP', 
with amino acid compositions consistent with that reported2 for activation peptide 
(TABLE l), were produced upon treatment of factor XI11 with thrombin? The ap- 
pearance in lower amounts (< 20%) of the second activation peptide (AP') may 
reflect the presence of a factor XI11 variant in the pooled plasma from which the 
protein was purified, or it could reflect partial hydrolysis at a Gln or Asn residue 
during purification. Treatment of factor XIII, or isolated AP and AP', with alkaline 
phosphatase had no effect on the relative amounts or elution positions of AP and 
A P ,  suggesting that activation peptide does not exist in different states of phospho- 
rylation as does fibrinopeptide A (FPA). Incubation of acidified mixtures of AP and 
AP' for several hours prior to HPLC resulted in the appearance of a shoulder on 
both the AP and AP' peaks, but no interconversion of the AP and AP'. The appearance 
of the shoulder may well reflect an N-0  acyl shift in the N-acetylseryl residue at the 
amino terminus of the activation peptide. Additional studies are required, however, 
to determine the structural basis for the different elution positions of AP and AP' 
and for the acid catalyzed alterations of these peptides. All kinetic parameters reported 
in this work are for the release of the major activation peptide, AP. 
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Studies of the dependence of the time dependence of the release of AP on the 
concentration of factor XIII indicated a value of 0.14 x 106M-'- '  for the specificity 
constant k,,/K, for thrombin-catalyzed release of AP. The value of K,, which was 
too high to determine accurately, was estimated to be 84 (2  30) pM. Comparison of 
the K,,, value for this process with estimates4 of 20 nM for the factor XI11 concentration 
in blood plasma, suggested thrombin-catalyzed activation of factor XI11 might be too 
inefficient to be physiologically significant unless the process was enhanced by other 
plasma constituents. FIGURE 1 shows that the presence of 0.45 pM fibrinogen produces 
a dramatic enhancement in the thrombin-catalyzed release of activation peptide. The 
promoting effect of fibrinogen increased with its concentration, and under the exper- 
imental conditions a near maximal effect was obtained at 0.9 pM fibrinogen, well 
below the plasma fibrinogen concentration (- 8 pM). When the concentration of 
fibrinogen was not in large excess of the factor XIII, there was a clearly discernible 
lag in the release of activation peptide. Under these conditions FPA appeared prior 
TABLE 1. Amino Acid Composition of Activation Peptides Derived from the Reaction 
of Human Factor XI11 with Human Thrombin 
~ 
Amino acid AP AP' Literature" 
Aspartic acid 4.4 4.1 5 
Glutamic acid 3.9 4.2 4 
Arginine 3.6 3.5 4 
Serine 3.0 2.6 3 
Glycine 3.3 2.8 3 
Threonine 2.8 2.1 3 
Proline 4.0 4.0 4 
Alanine 4.0 3.1 4 
Valine 3.0 3.1 3 
Leucine 1.8 2.1 2 
Phen ylalanine 1 .o 1.0 1 
From the amino acid sequence for the activation peptide reported in reference 2. 
to activation peptide, which in turn appeared prior to fibrinopeptide B, FPB (FIGURE 
2). This observation suggested that fibrin I or FPA, rather than fibrinogen, might be 
the immediate promoter of thrombin-catalyzed activation of factor XIII. Whereas 
FPA had no effect, fibrin I and I1 promoted thrombin-catalyzed release of AP from 
factor XIII. More importantly, as illustrated in FIGURE 3, the lag in the release of 
AP seen with fibrinogen was eliminated when fibrin I or I1 was the promoter. A 
kinetic analysis of the time dependence of the release of AP with fibrinogen as the 
promoter indicated that both fibrin I and I1 were equally effective in promoting 
thrombin-catalyzed activation of factor XIII. 
FIGURE 4 illustrates that the inhibitor of fibrin polymerization, glycyl-L-prolyl-L- 
arginyl-L-proline (GPRP),5r6 antagonized the promoting effect of fibrinogen. Because 
GPRP does not inhibit thrombin-catalyzed release of FPA from fibrinogen,' the 
simplest explanation of the antagonism by GPRP, is that fibrin monomer is not a 
promoter of thrombin-catalyzed release of AP from factor XIII, and that the ability 
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Go 75 . FIGURE 1. Thrombin-mediated release 
of activation peptide from 0.194 pM factor 
XI11 protomer in the presence and absence 
(inset) of 0.45 pM fibrinogen at pH 7.4 
(3772, p = 0.15), 0.1% PEG, and 0.565 
nM thrombin. (Janus et al.’ With permis- 
sion from Biochemistry.). TlUE (MINI 
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FIGURE 2. Sequence of release of fibrinopeptides and activation peptide from factor XI11 at 
pH 7.4 (37”C, p = 0.15) in 0.1% PEG by using 0.565 nM thrombin, 0.445 pM fibrinogen, and 
0.258 pM factor XI11 protomer. FPA, circles; FPB, squares; AP, triangles. The open circles 
and squares are data points obtained for the release of FPA and FPB in the absence of factor 
XIII. The ordinate (peptide fraction) is the quotient between the amount of peptide released at 
the indicated time and that released at completion of the reaction. (Janus et a].’ With permission 
from Biochemistry,) 
FIGURE 3. Time dependence of the release of AP, contain- 
ing factor XIII and either fibrinogen (A) or polymeric fibrin 
I (A) or fibrin I1 (0). Reaction mixtures contained 0.29 nM 
thrombin, 0.1 pM factor XIII, and 0.1 pM fibrinogen or 0.1 
pM (with respect to fibrin monomer) polymeric fibrin. Re- 
actions were camed out in 9.5 m M  phosphate buffer, pH 
7.4, 0.14 M NaCl, and 0.1% PEG, 37°C. (Lewis et al.’ With 
permission from Biochemistry.) 
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FIGURE 4. Thrombin-catalyzed release of 
AP from 0.10 p M  factor XIII, with 0.10 
pM fibrinogen added, in the absence (0) 
and presence of 0.10 (a), 0.21 (A), and 
0.490 mM (0) GPRP. Reactions were car- 
ried out as described in FIGURE 3. (Lewis 
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of GPRP to act as an antagonist is due to its suppression of the polymerization of 
fibrin. 
These studies of the fibrin-promoted thrombin-catalyzed release of AP from factor 
XI11 were done in the absence of calcium. In the absence of added calcium, enzymically 
active factor XIII, is not generated, because Ca” is required for steps subsequent to 
initial proteolysis in the reaction pathway for the conversion of factor XI11 to factor 
XIII,. Thus, in the absence of added Ca”, the fibrin in the reaction mixture remains 
non-cross-linked during measurements of the time dependence of AP release. Ca2+- 
promoted cross-linking of fibrin, however, could well alter its competence as a pro- 
moter. Therefore, we were prompted to determine the effect of Ca’ on thrombin- 
catalyzed release of AP. The plots in FIGURE 5 show that the presence of 1.4 mM 
Caz+ dramatically reduced the effectiveness of fibrinogen. FIGURE 6 shows that the 
effect of Caz+ can be partially reversed by the presence of plasma levels of fibrinogen. 
Interestingly, 1.4 mM Ca2+ had no effect on the unpromoted rate of release of AP 
TIME (MIN) FIBRINOGEN (uM) 
FIGURE 5. Panel A: Effect of Caz+ on the thrombin-catalyzed release of activation peptide 
(AP) from 0.10 pM factor XIXI in the presence of 0.10 pM fibrinogen, with (A) and without 
(A) 1.4 mM CaCI,. Also shown is the thrombin-mediated release of AP from 0.10 pM factor 
XI11 without fibrinogen and in the presence of 1.4 mM CaCI, (0). Reactions were carried out 
as described in FIGURE 3. Panel B: Dependence of thrombin-catalyzed release of AP from 0.10 
pM factor XI11 on the fibrinogen concentration in the absence (0) and presence (0) of added 
1 mM CaCI,. The ordinate is the fraction of AP released in 15 minutes. The reaction conditions 
are as described in FIGURE 3, except the buffer contains 0.01 M Tris instead of 9.5 mM phosphate. 
Control experiments showed that the fibrinogen-promoted release of AP from factor XIXI was 
the same in both buffers when Ca” was absent and that Ca2+ at 1 mM antagonized the effect 
of 0.1 p M  fibrinogen to the same extent in 0.01 M Tris and 9.5 mM phosphate buffer. (Lewis 
et a[.* With permission from Biochemistry.) 
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from factor XI11 observed in the absence of fibrinogen. The data in FIGURE 6 indicate 
that only a fraction of the AP is released at an enhanced rate in the presence of Ca2+. 
Thus, in the presence of 6 pM fibrinogen and 1 mM Caz+, the rate of AP release fell 
to the unpromoted rate after 20% of the AP had been released, whereas in the absence 
of added Ca”, the presence of 6 pM fibrinogen resulted in an enhanced rate of AP 
release until well over 90% of the AP was released. This observation indicated that 
the time-dependent loss in promoting activity might be due to cross-linking of fibrin 
by the activated factor XIII. Comparison of the time dependence of AP release and 
cross-linking of fibrin revealed that in the presence of Ca” the rate of AP release 
decreased to that seen in the absence of fibrin when 40% of the y chains of fibrin 
had become cross-linked. This result suggests that if non-cross-linked fibrin is a 
promoter and cross-linked fibrin is not, the promoting activity of fibrin must involve 
the interaction of more than one repeating unit of fibrin with each molecule of factor 
XIII. 
Consistent with the notion that formation of cross-links inactivated fibrin as a 
promoter of thrombin-catalyzed release of AP from factor XIII, the thiol reagent 
methyl methanethiosulfonate (MMTS) inactivated the activated factor XI11 and sub- 
stantially blocked the effect of Ca2+ (FIGURE 7). The failure of MMTS to block 
completely the inhibitory effect of CaZ+ suggests that Ca2+ may have secondary 
inhibitory effects on the fibrin-promoted reaction. 
Preliminary studies of the dependence of thrombin-catalyzed AP release on the 
concentration of factor XI11 and fibrin indicate that fibrin reduces the K,,, for the 
thrombin-catalyzed reaction, consistent with the possibility that fibrin forms a complex 
with factor XIII, which exhibits a high affinity for thrombin. Interestingly, y-thrombin, 
a form of thrombin that interacts poorly with fibrinogen, did not exhibit fibrin- 
promoted release of AP, although in the absence of fibrin, the rate of y-thrombin- 
catalyzed release of AP from factor XI11 was only fivefold lower than that of normal 
a-thrombin. This observation suggests the possibility that in fibrin-promoted a-throm- 
bin-catalyzed release of AP from factor XIII, the fibrin interacts with both the factor 
XI11 and thrombin and thereby presents the factor XI11 scissile bond to the active 
site of thrombin. 
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FIGURE 6. Thrombin-catalyzed release of AP from 0.10 p M  factor XI11 with 0.10 (O), 1 . 1  
(A), and 6 pM (0) fibrinogen in the presence of 1.0 mM CaC1,. The lowest line and ( 0 )  
represent the release of AP in the absence of fibrinogen (see FIGURE SA). Reaction conditions 
are as described in FIGURE 3, except that the curve for 1 . 1  p M  fibrinogen was determined in 
0.01 M Tris buffer. (Lewis eta/.‘ With permission from Biochemistry.) 
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FIGURE 7. Ability of MMTS to block the inhibitory 
factor XIII. Reaction mixtures contained 0.29 nM throm- 
bin, 1.1 pM fibrinogen, 0.1 pM factor XIII, and (r) no 
MMTS and 1 mM Ca2+, (0) 1.2 mM MMTS and 1 mM 
Ca2+, or (0 )  1.2 rnM MMTS and no added Ca2+. Re- 
the buffer species was 0.01 M Tris. (Lewis et aZ.’ With 
effects of CaZ+ on thrombin-catalyzed release of AP from 
t- 
2 0 4  
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action conditions are as described in FIGURE 3 except 
5 10 15 20  permission from Biochemistry.) 
TIME (MIN) 
The unique ability of polymeric non-cross-linked fibrin to promote thrombin- 
catalyzed release of AP could ensure that production of factor XI14 is initiated when 
its substrate is present and that production of additional factor XI14 is terminated 
upon cross-linking of fibrin y chains. This mode of regulation may serve to ensure 
against wasteful and possibly deleterious activation of factor XIII. It is our hypothesis 
that the final degree of cross-linking of a fibrin clot should increase with the amount 
of fibrin-associated factor XIII,, because the ability of a molecule of factor XIII, to 
catalyze formation of cross-links should be lost as the factor XIII, becomes enmeshed 
in the network of cross-links it produces. If this contention is correct, a high density 
of factor XIII, might be expected to result in a more heavily cross-linked clot, which 
would be more difficult for plasmin to dissolve, and more likely to lead to thrombosis. 
Thus, the regulation of factor XIII, described in this paper may be an important 
determinant for the formation of stable fibrin blood clots, which can later be efficiently 
dissolved by plasmin. Investigations are in progress to test this hypothesis. 
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